Anti TNF therapy and susceptibility for Coxiella burnetii infection

Anti TNF therapy and susceptibility for Coxiella burnetii infection - Anti TNF therapy and susceptibility for Coxiella burnetii infection

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35680

Enrollment

800

Registered

2011-09-06

Start date

2011-12-05

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coxiella burnetii infection Q fever

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Diagnosis of either rheumatoid arthritis (RA), arthritis psoriatica or bechterew disease • Residence in Q fever endemic area (defined by the Institute for Public Health and Environment (RIVM) as *core area*), as determined by the postal code of their home address. • Signed written informed consent ;For patients on anti-TNF therapy: • Treatment with TNFa blockers either infliximab, etanercept or adalimumab in an adequate dose according to the guidelines • Treatment with TNFa blockers is started before 01-01-2011 ;For patients not receiving anti-TNF therapy: • Treatment with DMARDs • No history of treatment with TNFa blockers

Exclusion criteria

Exclusion criteria: • Age under 18 years • Pregnancy or lactation • Lymphoma, lymphoproliferative syndromes and other hematologic malignancies • Chronic infections, including HIV, hepatitis B or C, mycobacterial disease

Design outcomes

Primary

Measure	Time frame
Serology indicative of chronic Q fever or past Q fever infection. In-vitro cytokine production and/or monocyte/macrophage polarisation. The presence of genetic polymorphisms in genes involved in the innate immunity.	—

Secondary

Measure	Time frame
geen	—

Countries

Netherlands

Outcome results